Rigel Pharmaceuticals upgraded to speculative buy as operational and financial momentum shift. The Gavreto acquisition has materially boosted revenue with approximately $245 million net present value, representing roughly half of the company's current market capitalization. Tavalisse demand has surged significantly, establishing a defensible market niche in immune thrombocytopenia treatment. Rezlidhia continues expanding beyond acute myeloid leukemia indications. Pipeline progress including the R289 program and Eli Lilly partnership, combined with strengthened cash position, supports near-term growth trajectory. However, investors should note the company requires new late-stage assets by 2028 to sustain long-term value creation and maintain competitive positioning in the pharmaceutical market.
Post from MarketNews_en
Log in to interact with content.